AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ATAI

Angermayer Christian sold (to issuer) 559,232 shares of ATAI

Angermayer Christian sold (to issuer) 559,232 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11. Filed jointly with Apeiron Investment Group Ltd. (10% owner).

Original reporting
SEC EDGAR · Angermayer Christian, Apeiron Investment Group Ltd.
Published Sep 11, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATAI
Bearish
medium confidence
Mentioned
$ATAI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAIBearishLow
01

Why it matters

The sale reduces insider stake to zero, potentially affecting investor perception.

02

Market read

Primary relevance is the insider sell; limited broader market effect.

03

What to watch

No disclosed price; sale could be part of a pre-arranged plan or tax considerations.

Relevance 4/10Novelty 4/10Timing: 2026-09-11 filing date

Background

SEC Form 4 filing discloses insider transactions required by regulation.

Company-level read

Ticker impact

$ATAIBearishMedium confidence
Context

Director and 10% owner Angermayer Christian sold 559,232 shares in a Form 4 filing.

Expected impact

Potential short-term downward pressure on ATAI stock.

Evidence & confidence

Large insider sale by a director often leads to negative market perception.

Market effects

Sector

Minimal impact on biotech sector beyond ATAI.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider may be selling for personal liquidity, not necessarily lack of confidence.

Key entities

  • Director
    Angermayer Christian

    10% owner of ATAI who sold 559,232 shares.

  • Co-owner
    Apeiron Investment Group Ltd.

    Joint filing co-owner with 10% stake.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATAI insider trading history →

Related articles

SEP 11
$LLYMedAI 8/10

$35 Billion Frog Drug Deal Explained: The Psychedelic Treatment That Could Change Depression Therapy

Eli Lilly is reportedly investing $35 billion in ATAI Life Sciences' psychedelic drug BPL-003, derived from a compound found in the Sonoran Desert toad, for treating depression. Clinical trials showed improvements in treatment-resistant depression patients, but long-term effects are still under study. The drug aims to promote neuroplasticity, potentially helping patients break negative thought patterns. Researchers caution that results do not prove a permanent cure.

vocal.media3 min
SEP 11
$LLYHighAI 9/10

Eli Lilly (LLY) Finalizes $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

Eli Lilly (LLY) completed its $2.8B acquisition of AtaiBeckley (ATAI) on September 11, 2026. AtaiBeckley shareholders received $6.75 per share plus contingent value rights (CVRs) worth up to $2.50 per share. AtaiBeckley shares rose 80% in the six months before the deal, closing at $7.35. The company will delist from Nasdaq. LLY shares closed at $1,119.26, down 0.33%.

blockonomi.com2 min
SEP 11
$LLYMedAI 9/10

Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline

Eli Lilly (LLY) completed its acquisition of AtaiBeckley, adding a clinical-stage portfolio of rapid-acting neuroplastogens to its neuroscience pipeline. The deal expands Lilly's focus on treatment-resistant depression and other mental health conditions, with BPL-003 as the lead program. Financial terms were not disclosed.

citybiz.co2 min
SEP 11
$LLYMedAI 8/10

Share AtaiBeckley Buyout – Minichart

Eli Lilly completed its $6.75-per-share acquisition of AtaiBeckley Inc., taking the company private. Shareholders received $6.75 in cash plus contingent value rights (CVRs) worth up to $2.50 more if milestones are met. AtaiBeckley's stock will be delisted from Nasdaq.

minichart.com.sg2 min